GlassScriptPhysician profile
Danielle Rae Glick
NPI 1104230531
$6,949.53
in general payments reported to CMS, 2019-2025
29 companies · $2,516 in 2025
The $2,516 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.38 · 2022: $142 · 2023: $1,710 · 2024: $2,562 · 2025: $2,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,669 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,668.50 |
| Education | $118.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,510.65 | 2021-2025 | |
| Mdd US Operations, LLC | $553.45 | 2024-2025 | Apokyn |
| Takeda Pharmaceuticals U.S.A., INC. | $535.16 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $529.93 | 2023-2025 | Epclusa |
| Janssen Biotech, INC. | $520.92 | 2023-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $505.73 | 2022-2025 | |
| Madrigal Pharmaceuticals | $491.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $320.48 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $243.12 | 2024-2025 | Zenpep, Vowst |
| Regeneron Healthcare Solutions, INC. | $228.33 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.42 | 2023-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $183.08 | 2023-2025 | Voquezna |
| Pfizer INC. | $169.86 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $142.56 | 2023-2024 | Linzess |
| Regeneron Pharmaceuticals, INC. | $124.41 | 2025 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $117.70 | 2024-2025 | Omvoh |
| Organon LLC | $103.10 | 2023-2025 | Hadlima |
| Celgene Corporation | $91.82 | 2023-2024 | Zeposia |
| Celltrion USA INC. | $72.20 | 2023-2024 | Zymfentra, Yuflyma |
| Ferring Pharmaceuticals INC. | $53.63 | 2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $39.42 | 2023-2025 | Ocaliva |
| Boston Scientific Corporation | $37.70 | 2023 | Coveredge 32, Wavewriter Alpha Prime 16 |
| Qol Medical, LLC | $33.94 | 2025 | Sucraid |
| Novo Nordisk INC | $29.67 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.67 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $21.35 | 2025 | Iqirvo |
| Allergan, INC. | $21.35 | 2022 | |
| Nestle Healthcare Nutrition INC. | $20.83 | 2023 | |
| Braintree Laboratories, INC. | $19.46 | 2025 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.